An Italian Perspective on the Abuse of Dominant Position in the Pharmaceutical Sector and Standard of Proof: The Pfizer Case.

In this article published in ThoughtLeaders4 Competition Magazine (Issue 9), Simone Gambuto explores the well-known 102 tfue follow-on Pfizer case. The focus lies on the standard of proof required by civil court to award damages that follows abusive practices in the highly sensitive pharmaceutical sector. The piece provides valuable insights into the evolution of private antitrust enforcement in Italy. 

This article was first published in ThoughtLeaders4 Competition Magazine.

Publish date: 21/05/2025